 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | ABO1009-DP / Suzhou Abogen Biosci
Enrollment closed: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19 Omicron) mRNA Vaccine (Phase 1) (clinicaltrials.gov) - Sep 21, 2022
P1/2, N=48, Active, not recruiting, Sponsor: Suzhou Abogen Biosciences Co., Ltd.
Recruiting --> Active, not recruiting
- || ABO1009-DP / Suzhou Abogen Biosci
Enrollment open: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19 Omicron) mRNA Vaccine (Phase 1) (clinicaltrials.gov) - Aug 31, 2022
P1/2, N=48, Recruiting, Sponsor: Suzhou Abogen Biosciences Co., Ltd.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || ABO-CoV.617.2 / Suzhou Abogen Biosci, ABO1009-DP / Suzhou Abogen Biosci
Enrollment closed: A Study to Evaluate Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19) mRNA Vaccines (clinicaltrials.gov) - Aug 23, 2022
P1, N=60, Active, not recruiting, Sponsor: Suzhou Abogen Biosciences Co., Ltd.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| ABO-CoV.617.2 / Suzhou Abogen Biosci, ABO1009-DP / Suzhou Abogen Biosci
Enrollment open: A Study to Evaluate Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19) mRNA Vaccines (clinicaltrials.gov) - Jul 23, 2022
P1, N=60, Recruiting, Sponsor: Suzhou Abogen Biosciences Co., Ltd.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | ABO1009-DP / Suzhou Abogen Biosci
Trial primary completion date: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19 Omicron) mRNA Vaccine (Phase 1) (clinicaltrials.gov) - Jul 16, 2022
P1/2, N=48, Not yet recruiting, Sponsor: Suzhou Abogen Biosciences Co., Ltd.
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2022 --> Dec 2022
- | ABO-CoV.617.2 / Suzhou Abogen Biosci, ABO1009-DP / Suzhou Abogen Biosci
New P1 trial: A Study to Evaluate Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19) mRNA Vaccines (clinicaltrials.gov) - Jun 27, 2022
P1, N=60, Not yet recruiting, Sponsor: Suzhou Abogen Biosciences Co., Ltd.
- | ABO1009-DP / Suzhou Abogen Biosci
New P1/2 trial: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19 Omicron) mRNA Vaccine (Phase 1) (clinicaltrials.gov) - Jun 26, 2022
P1/2, N=48, Not yet recruiting, Sponsor: Suzhou Abogen Biosciences Co., Ltd.